804 Shares in Novo Nordisk A/S (NYSE:NVO) Acquired by Physician Wealth Advisors Inc.

Physician Wealth Advisors Inc. bought a new position in shares of Novo Nordisk A/S (NYSE:NVO) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 804 shares of the company’s stock, valued at approximately $69,000.

Other institutional investors also recently modified their holdings of the company. RWA Wealth Partners LLC grew its position in Novo Nordisk A/S by 48.8% during the 4th quarter. RWA Wealth Partners LLC now owns 90,823 shares of the company’s stock worth $7,813,000 after acquiring an additional 29,787 shares during the last quarter. Intrust Bank NA increased its stake in shares of Novo Nordisk A/S by 3.3% in the fourth quarter. Intrust Bank NA now owns 8,717 shares of the company’s stock valued at $750,000 after buying an additional 281 shares during the period. Brown Brothers Harriman & Co. raised its holdings in Novo Nordisk A/S by 60.9% in the 4th quarter. Brown Brothers Harriman & Co. now owns 60,121 shares of the company’s stock valued at $5,172,000 after buying an additional 22,754 shares during the last quarter. Horizon Investment Services LLC boosted its position in Novo Nordisk A/S by 26.0% during the 4th quarter. Horizon Investment Services LLC now owns 3,699 shares of the company’s stock worth $318,000 after buying an additional 764 shares during the period. Finally, Orion Portfolio Solutions LLC grew its holdings in Novo Nordisk A/S by 10.5% during the 4th quarter. Orion Portfolio Solutions LLC now owns 297,996 shares of the company’s stock worth $25,634,000 after acquiring an additional 28,331 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Up 0.4 %

Novo Nordisk A/S stock opened at $69.58 on Tuesday. The company has a market capitalization of $312.24 billion, a PE ratio of 21.15, a PEG ratio of 0.90 and a beta of 0.42. Novo Nordisk A/S has a 12-month low of $66.88 and a 12-month high of $148.15. The firm’s fifty day moving average is $82.15 and its 200 day moving average is $98.17. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. As a group, sell-side analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The company also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be paid a $0.7874 dividend. This represents a yield of 1.2%. The ex-dividend date of this dividend is Monday, March 31st. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. Novo Nordisk A/S’s dividend payout ratio (DPR) is 47.72%.

Analyst Ratings Changes

A number of research firms recently weighed in on NVO. StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Friday, March 21st. Morgan Stanley initiated coverage on Novo Nordisk A/S in a report on Wednesday, February 12th. They issued an “equal weight” rating on the stock. Kepler Capital Markets upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Thursday, March 13th. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, Stifel Nicolaus cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, March 3rd. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Novo Nordisk A/S has an average rating of “Moderate Buy” and a consensus price target of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.